Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001562180-22-004978
Filing Date
2022-06-09
Accepted
2022-06-09 17:00:10
Documents
2
Period of Report
2022-06-08

Document Format Files

Seq Description Document Type Size
1 PRIMARY DOCUMENT primarydocument.html 4  
1 PRIMARY DOCUMENT primarydocument.xml 4 6281
2 POA UPDATED JUNE 2022 poa_mwolf2022.txt EX-24 3467
  Complete submission text file 0001562180-22-004978.txt   11093
Mailing Address 245 FIRST STREET CAMBRIDGE MA 02142
Business Address 245 FIRST STREET CAMBRIDGE MA 02142 617-871-2098
Akebia Therapeutics, Inc. (Issuer) CIK: 0001517022 (see all company filings)

EIN.: 208756903 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations

Mailing Address C/O AKEBIA THERAPEUTICS, INC. 245 FIRST STREET CAMBRIDGE MA 02142
Business Address
Wolf Myles (Reporting) CIK: 0001808317 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-36352 | Film No.: 221006662